Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems. The company primarily focuses on treating smoking cessation. Its lead product drug candidates include MYCO-001, MYCO-002, MYCO003, and MYCO-004. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Qual è il simbolo azionario di Noveris Health Sciences?▼
A seconda della borsa, il simbolo dell’azione può variare. Ad esempio, alla borsa le azioni di Noveris Health Sciences sono negoziate con il simbolo 0NF1.MU.
Quanti dipendenti ha Noveris Health Sciences?▼
Al aprile 11, 2026, l'azienda conta 3 dipendenti.
In quale settore opera Noveris Health Sciences?▼
Noveris Health Sciences opera nel settore Salute e Benessere.
Quando Noveris Health Sciences ha completato lo split azionario?▼
Noveris Health Sciences non ha effettuato alcuno split di recente.
Dove si trova la sede di Noveris Health Sciences?▼
La sede di Noveris Health Sciences si trova a Vancouver, Canada.